PT-141 (Bremelanotide) 10 mg

The active metabolite of melanotan II, developed as a drug in its own right. It acts on the central nervous system rather than the peripheral vasculature: that is the essential difference from phosphodiesterase inhibitors. It has regulatory approval in the United States.

CAS: 189691-06-3
Formula: C50H68N14O10
Molecular weight: 1025.2 g/mol
Purity: ≥ 98% verified by HPLC
Presentation: Amber glass vial with lyophilized powder, vacuum sealed.
: Includes 3 ml BAC waterIn the same box, at no cost.

$80 USD

How it works

Agonism of the melanocortin receptors MC3R and MC4R in the central nervous system.
Acts on desire pathways, not on peripheral blood flow.
Independent of vascular stimulus, so it does not interact with nitrates by that route.

Qué dice la evidencia

Phase 3 trials with improvement in sexual desire versus placebo.

Route described in the studies

Route: Subcutaneous, about 45 minutes before the intended effect. Not for daily use.
Preparation: Reconstitute with BAC WATER without shaking.
Application site: Alternate the site with each application.

Documented effects

Nausea, the most frequent effect and dose-dependent
Facial flushing
Headache
Transient rise in blood pressure with a fall in heart rate

When it is not used

Uncontrolled hypertension
Established cardiovascular disease
Pregnancy and breastfeeding

Storage

Lyophilised: 2 to 8 °C protected from light.
Reconstituted: 2 to 8 °C, within 30 days.
Shipping: Stable at ambient temperature in lyophilized form.

Preguntas frecuentes

Why the limit of eight applications a month?

It is the maximum evaluated in the phase 3 trials, set by the blood pressure profile with repeated applications.

Research use only

Este compuesto se vende únicamente para investigación de laboratorio y desarrollo analítico. No es un medicamento, no está aprobado por ninguna autoridad sanitaria, y no se vende para diagnosticar, tratar, curar ni prevenir ninguna enfermedad. No es apto para consumo humano ni animal.